STANISIC, S.; CICCHETTI, A.; PORTA, C.; PROCOPIO, G.; BERTO, P. Cost-effectiveness of cabozantinib in second-line treatment of metastatic renal cell cancer (mRCC) in Italy. Global and Regional Health Technology Assessment, [S. l.], v. 5, n. 1, 2018. DOI: 10.33393/grhta.2018.434. Disponível em: https://journals.aboutscience.eu/index.php/grhta/article/view/434. Acesso em: 22 jul. 2024.